Biomedicines,
Год журнала:
2025,
Номер
13(3), С. 720 - 720
Опубликована: Март 15, 2025
Sodium–glucose
cotransporter-2
inhibitors
(SGLT2i)
are
a
specific
class
of
drugs
originally
developed
for
treating
type
2
diabetes
mellitus.
Subsequently,
studies
demonstrated
that
their
action
was
not
limited
to
glycemic
control
but
could
also
have
positive
effects
on
other
outcomes,
particularly
at
the
cardiovascular
level.
Indeed,
due
diuretic
effect,
SGLT2i
improve
clinical
chronic
heart
failure
and
reduce
risk
rehospitalization.
In
addition,
reported
protective
effect
major
events
mortality.
More
recently,
it
has
been
suggested
prescription
after
an
acute
myocardial
infarction
may
possible
inflammation,
arrhythmias,
ventricular
remodeling.
Here,
we
reviewed
focused
in
patients
treated
with
percutaneous
coronary
intervention.
Pharmacological Research,
Год журнала:
2022,
Номер
187, С. 106597 - 106597
Опубликована: Дек. 5, 2022
To
investigate
in-hospital
and
long-term
prognosis
in
T2DM
patients
presenting
with
acute
myocardial
infarction
(AMI)
treated
SGLT2-I
versus
other
oral
anti-diabetic
agents
(non-SGLT2-I
users).
Pharmacology & Therapeutics,
Год журнала:
2025,
Номер
270, С. 108861 - 108861
Опубликована: Апрель 15, 2025
Sodium-glucose
co-transporter
2
(SGLT2)
inhibitors
are
oral
antidiabetic
agents
that
have
shown
significant
improvements
in
cardiovascular
and
renal
outcomes
among
patients
with
heart
failure
(HF),
regardless
of
diabetic
status,
establishing
them
as
a
cornerstone
therapy.
In
addition
to
glycemic
control
the
osmotic
diuretic
effect,
inhibition
SGLT2
improves
endothelial
function
vasodilation,
optimizing
myocardial
energy
metabolism
preserving
cardiac
contractility.
Moreover,
may
exhibit
anti-inflammatory
properties
attenuate
acute
ischemia/reperfusion
injury,
thereby
reducing
infarct
size,
enhancing
left
ventricular
function,
mitigating
arrhythmias.
These
pleiotropic
effects
demonstrated
efficacy
across
various
conditions,
ranging
from
chronic
coronary
syndromes
extending
arrhythmias,
valvular
disease,
cardiomyopathies,
cardio-oncology,
cerebrovascular
disease.
This
review
provides
an
overview
current
literature
on
potential
mechanisms
underlying
effectiveness
wide
range
diseases
beyond
HF.
Current Pharmaceutical Design,
Год журнала:
2024,
Номер
30(27), С. 2109 - 2119
Опубликована: Июнь 24, 2024
Atherosclerotic
Cardiovascular
Disease
(ASCVD)
is
still
one
of
the
leading
causes
death
globally,
with
Coronary
Artery
(CAD)
being
most
prevalent
form
ASCVD.
Patients
type
2
Diabetes
Mellitus
(DM)
experience
an
increased
risk
for
ASCVD
during
disease
course,
CAD
common
cause
among
affected
individuals,
resulting
in
shorter
life
expectancy
and
morbidity
survivors.
Recently,
novel
classes
anti-diabetic
drugs,
namely
Sodium-Glucose
Co-Transporter-
(SGLT-2)
inhibitors
Glucagon-Like
Peptide-1
(GLP-1)
receptor
agonists,
have
shown
impressive
cardio-renal
benefits
patients
DM,
while
they
might
decrease
even
absence
baseline
DM.
However,
there
no
evidence
to
date
regarding
their
safety
efficacy
setting
acute
coronary
syndrome
(ACS)
event,
regardless
concomitant
This
study
aims
provide
a
detailed,
updated
presentation
currently
available
clinical
concerning
potential
role
SGLT-2
GLP-1
agonists
ACS,
highlight
whether
those
drug
could
be
utilized
as
adjuncts
standard-of-care
treatment
this
specific
patient
population,
along
short-
long-term
cardiovascular
benefits.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(18), С. 5408 - 5408
Опубликована: Сен. 12, 2024
Atrial
fibrillation
(AF)
is
the
most
prevalent
arrhythmia
among
adults
worldwide,
frequently
co-occurring
with
comorbidities
such
as
Heart
Failure
(HF)
and
Type
2
Diabetes
Mellitus
(T2DM).
This
association
contributes
to
increased
morbidity
mortality,
elevated
healthcare
costs,
diminished
quality
of
life.
Consequently,
preventing
or
delaying
onset
recurrence
AF
crucial
for
reducing
incidence
complications.
Sodium-glucose
cotransporter
inhibitors
(SGLT2is),
due
their
multifaceted
pharmacological
actions,
have
been
proposed
potential
therapeutic
agents
in
management
AF.
However,
current
evidence
from
both
animal
models
clinical
studies
remains
inconclusive.
narrative
literature
review
aims
provide
a
comprehensive
analysis
existing
on
impact
SGLT2is
prevalence,
new-onset,
diabetic
populations
patients
HF.
Numerous
observational
studies,
predominantly
retrospective,
suggest
consistent
reduction
risk
SGLT2is,
while
randomized
controlled
trials
(RCTs)
yielded
mixed
results,
some
demonstrating
benefits
others
not
reaching
statistical
significance.
The
heterogeneity
study
outcomes,
population
characteristics,
follow-up
duration,
specific
used,
well
biases,
underscore
need
further
extensive
rigorous
RCTs
establish
definitive
conclusions
elucidate
underlying
mechanisms.
Scientific Reports,
Год журнала:
2023,
Номер
13(1)
Опубликована: Дек. 8, 2023
Abstract
Novel
hypoglycemic
agents,
sodium-glucose
cotransporter
2
inhibitors
(SGLT2i),
have
shown
protective
effects
against
anthracycline
(AC)-induced
cardiotoxicity
and
exhibit
partial
anticancer
in
animal
models.
However,
clinical
evidence
for
this
is
scarce.
This
study
aimed
to
evaluate
whether
SGLT2i
improve
the
outcomes
of
patients
with
type
diabetes
mellitus
(T2DM)
undergoing
AC-containing
chemotherapy.
A
total
81,572
who
underwent
AC
chemotherapy
between
2014
2021
were
recruited
from
a
nationwide
Korean
cohort.
Patients
classified
into
three
groups:
T2DM
taking
(n
=
780)
other
agents
excluding
(non-SGLT2i;
n
3,455)
during
chemotherapy,
non-DM
group
77,337).
The
outcome
was
composite
heart
failure
hospitalization,
acute
myocardial
infarction,
ischemic
stroke,
death.
After
propensity
score
matching,
779
users
compared
7800
2,337
non-SGLT2i
users.
had
better
(adjusted
hazard
ratio
[HR]
0.35,
95%
confidence
interval
[95%
CI]
0.25–0.51)
HR
0.47,
CI
0.32–0.69).
In
conclusion,
may
contribute
improving
through
an
emulated
target
trial
using
cohort
data.
